GH — Guardant Health, Inc.

Summary of Guardant Health Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $302 million, up 48% year-over-year.
• Oncology Revenue: $205 million, a 36% increase, with test volumes rising 47% to approximately 86,000.
• Biopharma & Data Revenue: $53 million, up 17%.
• Screening Revenue: $42 million, significantly up from $6 million in Q1 2025, driven by approximately 44,000 Shield tests.
• Non-GAAP Gross Margin: 66%, slightly improved from 65% year-over-year.
• Adjusted EBITDA Loss: $59 million, consistent with Q1 2025.
• Free Cash Flow Burn: $71 million, compared to $67 million in the prior year.
• Cash and Investments: Approximately $1.2 billion at quarter-end.

2. Strategic Updates and Business Highlights

• Commercial Growth: Achieved the fastest year-over-year revenue growth in five years, surpassing the $1 billion trailing 12-month revenue milestone.
• Oncology Portfolio: Strong performance from Guardant360 Liquid (30% volume growth) and Reveal (over 100% volume growth), reflecting expanding adoption and new clinical applications.
• Shield Launch: Successful direct-to-consumer campaigns and partnerships (notably with Quest Diagnostics) contributed to significant volume growth and high adherence rates (over 90%).
• Data Expansion: The company is building a comprehensive data repository with insights from over 1 million patient samples, enhancing its InfinityAI platform for therapeutic discovery.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised to $1.30 billion to $1.32 billion for FY 2026, representing growth of 32% to 34%.
• Oncology Revenue Growth: Expected to be 28% to 29%, with volume growth exceeding 35%.
• Screening Revenue: Projected at $186 million to $198 million, driven by Shield volume of approximately 230,000 to 245,000 tests.
• Operating Expenses: Expected to be in the range of $1.05 billion to $1.07 billion, reflecting growth of 16% to 18%.
• Free Cash Flow Burn: Anticipated to improve to $185 million to $195 million for the full year.

4. Bad News, Challenges, or Points of Concern

• FDA Approval Risks: The recent negative vote from the Oncologic Drugs Advisory Committee regarding camizestrant could impact future product approvals and market positioning.
• ASP Expectations: Anticipated decline in ASP for Shield tests as the company expands its commercial patient base, which may affect revenue in the latter half of the year.
• Competitive Pressures: Increased competition from other companies in the diagnostics space, including Roche and Abbott, could impact market share and pricing strategies.

5. Notable Q&A Insights

• Confidence in Shield Volume: Management expressed strong confidence in continued volume growth for Shield, attributing recent momentum to successful marketing initiatives and partnerships.
• Guardant360 Growth Drivers: The growth in Guardant360 is attributed to enhanced capabilities and broader adoption among oncologists, with expectations for continued strength in the oncology segment.
• Regulatory Path for Multi-Cancer Detection: The company is optimistic about building the largest clinical database for Multi-Cancer Detection outcomes, with ongoing efforts to meet regulatory milestones.
• Sales Force Expansion: Plans to continue investing in the sales force and marketing initiatives to support growth, with a focus on improving sales rep productivity.

Overall, Guardant Health demonstrated strong financial performance in Q1 2026, with significant growth across its product lines and strategic initiatives aimed at expanding its market presence and capabilities. However, the company faces challenges related to regulatory approvals and competitive pressures that could impact future growth trajectories.